Morbidity Table 12 provides an outline of all complications and the incidence of each complication type for all RNSH cardiac surgery cases in 2021. Notes: • Each case can have multiple complications and returns to theatre (RTT) in the postoperative period. • Each complication within the table has been counted as a separate incident. • Patients can have multiple reasons for cardiac inotrope or vasopressor use. Of the 220 patients who experienced cardiac inotrope or vasopressor use, almost all used it for >4 hours post-operatively. Of those patients, 65.0% used it for low SVR syndrome and 50.0% used it for low cardiac output syndrome.
Complication
% of total
n
New pulmonary
78
22.2
Ventilation prolonged (>24 hrs)
39
11.1
Pulmonary embolism
3
0.9
Pneumonia
36
10.2
New infection
46
13.1
Deep sternal wound
7
2.0
Complication
% of total
n
Superficial access wound infection
26
7.4
Return to theatre (RTT) total
54
15.3
Donor site deep wound
4
1.1
Re-op bleeding / tamponade
17
4.8
Deep access wound of parasternal site
1
0.3
Re-op deep sternal wound infection
6
1.7
Septicaemia
8
2.3
Re-op deep thoracotomy wound infection
1
0.3
New vascular
5
1.4
Re-op insertion of pacemaker/AICD
15
4.3
New other
24
6.8
Re-op other cardiac
6
1.7
Anticoagulant complications
6
1.7
Re-op other non-cardiac
25
7.1
Gastrointestinal tract complications
6
1.7
New renal insufficiency
25
7.1
Multi-system failure
12
3.4
Pre-/post-operative MI
3
0.9
New neurologic
18
5.1
Pre-/post-operative cardiogenic shock
15
4.3
Table 12. Overall complications (continued)
Cardiac inotrope or vasopressor use
220
62.5
>4 hours post-operatively
219
62.2
For low cardiac output syndrome
110
31.2
For low SVR syndrome
143
40.6
New cardiac arrhythmia
116
33
New neurologic
18
5.1
Stroke permanent
10
2.8
Stroke transient
3
0.9
Continuous coma ≥ 24hrs
5
1.4
Table 12. Overall complications
26
27
Cardiac Surgery Annual Report 2021
Cardiac Surgery Annual Report 2021
Made with FlippingBook - professional solution for displaying marketing and sales documents online